Capricor Therapeutics’ (CAPR) Buy Rating Reiterated at HC Wainwright
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $77.00 price objective on the biotechnology company’s stock. Other research analysts also recently issued reports about the stock. Oppenheimer cut their price […]
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $77.00 price objective on the biotechnology company’s stock. Other research analysts also recently issued reports about the stock. Oppenheimer cut their price […]
